A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

导出原文传递

翻译打印收藏纠错

作者： Maddocks, Kami ^[1] ; Hertlein, Erin ^[2] ; Chen, Timothy L. ^[3] ; Wagner, Amy J. ; Ling, Yonghua ; Flynn, Joseph ; Phelps, Mitch ; Johnson, Amy J. ; Byrd, John C. ; Jones, Jeffrey A.

作者单位： Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA ^[1] Ohio State Univ, Coll Pharm, Div Pharmaceut, 500 W 12Th Ave, Columbus, OH 43210 USA ^[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA ^[3]

发布时间 2017-06-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia and lymphoma

2016年57卷9期

2212-2215页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Leukemia and lymphoma

相似文献

Leukemia and lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Leukemia and lymphoma

相似文献

Leukemia and lymphoma

相关期刊

检索历史清除